Balita.org: Your Premier Source for Comprehensive Philippines News and Insights! We bring you the latest news, stories, and updates on a wide range of topics, including politics, culture, economy, and more. Stay tuned to know everything you wish about your favorite stars 24/7.

Contacts

  • balita.org

Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia

BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) — Bio-Convert ApS («Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (»Nordicus” or the «Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces the groundbreaking development of QR-02, a unique and proprietary oral topical treatment designed to address oral leukoplakia with moderate to severe dysplasia, a potentially precancerous condition affecting millions worldwide.

Addressing a Critical Unmet Medical Need

Oral leukoplakia is characterized by white patches or plaques in the mouth, and when accompanied by dysplasia (abnormal cell growth), it becomes a marker of disease progression. Alarmingly, 10-30% of these patients may develop oral cancer, which has a five-year mortality rate exceeding 50%.

With 15.5 million oral leukoplakia patients in the U.S. and EU alone, there is an urgent need for an effective treatment to prevent disease progression. Given that 80% of leukoplakia lesions occur in the oral cavity, a therapy that remains in place for an extended period is critical for success.

QR-02: A Game-Changing Approach

Bio-Convert's QR-02 introduces a novel mucoadhesive oral formulation designed to adhere to the oral cavity for an extended period of 12-24 hours-a major advancement over traditional treatments, which last only 15-20 minutes due to the washout effect of saliva. This extended retention period significantly enhances drug efficacy and improves patient outcomes.

QR-02's active ingredient, imiquimod, is already FDA-approved for treating Actinic Keratosis, External Genital Warts, and Superficial Basal Cell Carcinoma (sBCC)-all superficial skin conditions. However, QR-02 is uniquely formulated for oral application, providing new hope for patients with oral leukoplakia and may also be beneficial in treating conditions that subsequently could occur in such patients.

Advertisement

Potential for a Transformative Impact

The goal of QR-02 is to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia, an outcome that would mark a

Read more on manilatimes.net
DMCA